ReviewFrontiers in pharmacology2016
Biomarkers in DILI: One More Step Forward.
Review in Frontiers in pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The diagnostic role of miR-122 in drug-induced liver injury: A systematic review and meta-analysis.Medicine · 2018Pooled it
- Haloperidol-induced liver injury in pregnancy: A rare case report and review of drug-induced hepatitis.Radiology case reports · 2026Article
- A large-scale human toxicogenomics resource for drug-induced liver injury prediction.Nature communications · 2025Article
- Short communication: miRNA122 interrogation via PCR-Free method to track liver recovery.PloS one · 2025Article
- Review
- In silico modeling-based new alternative methods to predict drug and herb-induced liver injury: A review.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2023Review
- Metabolomic Analysis of Pediatric Patients with Idiosyncratic Drug-Induced Liver Injury According to the Updated RUCAM.International journal of molecular sciences · 2023Observational
- Chemokines in Primary Liver Cancer.International journal of molecular sciences · 2022Review
- Article
- Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction.Acta pharmaceutica Sinica. B · 2021Review
- Systems analysis of miRNA biomarkers to inform drug safety.Archives of toxicology · 2021Review
- Metabolomic analysis to discriminate drug-induced liver injury (DILI) phenotypes.Archives of toxicology · 2021Observational
- Overview of drug induced liver injury in Brazil: What is the role of public health policy on the evidence?World journal of gastrointestinal pharmacology and therapeutics · 2021Article
- Drug-Induced Liver Injury: Clinical Evidence of N-Acetyl Cysteine Protective Effects.Oxidative medicine and cellular longevity · 2021Review
- The evolution of strategies to minimise the risk of human drug-induced liver injury (DILI) in drug discovery and development.Archives of toxicology · 2020Review
- Evaluation of histophysiological alterations associated with ketoprofen administration in albino NMRI mice.Naunyn-Schmiedeberg's archives of pharmacology · 2020Article
- Article
- Diagnostic Biomarkers in Liver Injury by Drugs, Herbs, and Alcohol: Tricky Dilemma after EMA Correctly and Officially Retracted Letter of Support.International journal of molecular sciences · 2019Review
- Review
- Drug-Induced Liver Injury: Highlights of the Recent Literature.Drug safety · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite being relatively rare, drug-induced liver injury (DILI) is a serious condition, both for the individual patient due to the risk of acute liver failure, and for the drug development industry and regulatory agencies due to associations with drug development attritions, black box warnings, and postmarketing withdrawals. A major limitation in DILI diagnosis and prediction is the current lack of specific biomarkers. Despite refined usage of traditional liver biomarkers in DILI, reliable disease outcome predictions are still difficult to make. These limitations have driven the growing interest in developing new more sensitive and specific DILI biomarkers, which can improve early DILI prediction, diagnosis, and course of action. Several promising DILI biomarker candidates have been discovered to date, including mechanistic-based biomarker candidates such as glutamate dehydrogenase, high-mobility group box 1 protein and keratin-18, which can also provide information on the injury mechanism of different causative agents. Furthermore, microRNAs have received much attention lately as potential non-invasive DILI biomarker candidates, in particular miR-122. Advances in "omics" technologies offer a new approach for biomarker exploration studies. The ability to screen a large number of molecules (e.g., metabolites, proteins, or DNA) simultaneously enables the identification of 'toxicity signatures,' which may be used to enhance preclinical safety assessments and disease diagnostics. Omics-based studies can also provide information on the underlying mechanisms of distinct forms of DILI that may further facilitate the identification of early diagnostic biomarkers and safer implementation of personalized medicine. In this review, we summarize recent advances in the area of DILI biomarker studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.